European Archives of Psychiatry and Clinical Neuroscience

, Volume 248, Issue 4, pp 209–211

Clozapine efficacy in tardive dyskinesia in schizophrenic patients

Authors

  • D.P. Bassitt
    • Institute of Psychiatry, Medical School, University of São Paulo, Av. Dr. Ovidio Dires de Campos, S/N, São Paulo - SP, CEP 05403-010, Brasil
  • Mário Rodrigues Louzã Neto
    • Institute of Psychiatry, Medical School, University of São Paulo, Av. Dr. Ovidio Dires de Campos, S/N, São Paulo - SP, CEP 05403-010, Brasil
Short communication

DOI: 10.1007/s004060050039

Cite this article as:
Bassitt, D. & Louzã Neto, M. European Archives of Psychiatry and Clinical Neurosciences (1998) 248: 209. doi:10.1007/s004060050039

Abstract

Tardive dyskinesia (TD) is a long-term severe complication of antipsychotic treatment, with mean prevalence of 20–35%. The aim of this study was to evaluate effects of clozapine in severe TD. In an open trial seven patients with schizophrenia and severe TD were given clozapine for 6 months. Tardive dyskinesia severity was evaluated with AIMS and ESRS and schizophrenic psychopathology with PANSS. Clozapine mean dose at the end of the study was 392.86 mg/day. A mean reduction of 52% was observed in ESRS scores for TD. Two patients also had dystonic movements, and there was 50% reduction in one of them and complete remission in the other. There was also a 27% mean reduction in PANSS scores. Clozapine seems to be an alternative in the treatment of schizophrenic patients with severe TD.

Key words Tardive dyskinesiaTreatmentClozapineSchizophrenia

Copyright information

© Springer-Verlag Berlin Heidelberg 1998